Pre-made Izokibep benchmark antibody (trivalent bispecific, anti-ALB;IL17A/IL17 therapeutic antibody, Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;CTLA-8/CTLA8A Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Izokibep benchmark antibody (trivalent bispecific, anti-ALB;IL17A/IL17 therapeutic antibody, Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;CTLA-8/CTLA8A Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Izokibep (IMG-020), is a novel bispecific fusion protein, potently targeting both subunits of IL-17A as well as albumin.
Izokibep has been specifically designed to utilize the strengths of Affibody’s technology platform to create a very small protein drug (18 kDa, approximately one eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM, approximately 1000X of a typical IL-17 antibody) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin. These features lead to the potential for best-in-class efficacy in a convenient, less frequent and at-home subcutaneous administration.